While the American Urological Association recommends PSA as the best screening tool in assessing PCa risk level and ultimately selecting patients for biopsy [12], others have discussed factors that modify the sensitivity and specificity of serum PSA, such as body mass index (BMI) and prostate weight (PW) [4, 13–15]. Here, KLK3 is linked to posterior cortical atrophy.